STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

BACKGROUND: Poly (ADP-ribose) polymerase (PARP) inhibition (PARPi) has demonstrated potent therapeutic efficacy in patients with BRCA-mutant ovarian cancer. However, acquired resistance to PARPi remains a major challenge in the clinic. METHODS: PARPi-resistant ovarian cancer mouse models were genera...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Liya, Wang, Qiwei, Martincuks, Antons, Kearns, Michael J, Jiang, Tao, Lin, Ziying, Cheng, Xin, Qian, Changli, Xie, Shaozhen, Kim, Hye-Jung, Launonen, Inga-Maria, Färkkilä, Anniina, Roberts, Thomas M, Freeman, Gordon J, Liu, Joyce F, Konstantinopoulos, Panagiotis A, Matulonis, Ursula, Yu, Hua, Zhao, Jean J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827255/
https://www.ncbi.nlm.nih.gov/pubmed/36609487
http://dx.doi.org/10.1136/jitc-2022-005627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827255/
https://www.ncbi.nlm.nih.gov/pubmed/36609487
http://dx.doi.org/10.1136/jitc-2022-005627

Ejemplares similares